[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
May 1990

Radioimmunotherapy of Human Colon Cancer in Nude Mice

Author Affiliations

From the Department of General Oncologic Surgery (Drs Buras, B. G. Beatty, Harris, and J. D. Beatty), the Division of Diagnostic Radiology (Dr Williams), and the Department of Biostatistics (Dr Hill), City of Hope National Medical Center, Duarte, Calif; and Hybritech Inc, San Diego, Calif (Mr Wanek).

Arch Surg. 1990;125(5):660-664. doi:10.1001/archsurg.1990.01410170108023

• Nude mice bearing subcutaneous human colon cancer xenografts (LS174T) were treated with 120 μCi of yttrium 90—labeled anti-carcinoembryonic antigen monoclonal antibodies (specific therapy), 120 μCi of90Y-labeled anti-melanoma monoclonal antibodies (nonspecific therapy), or phosphate-buffered saline solution (no treatment control). Mean (±SD) tumor growth rates (percent increase per day) over the first 30 days of the study were as follows: 0.6%±0.2% per day (specific therapy); 17.7%±5.7% per day (nonspecific therapy); and 30.5%±4.2% per day (control). In all three groups, tumors over 1 g had similar doubling times (5.74±0.71 d). Specific therapy caused a lag in tumor growth corresponding to a 3-logarithm cell kill. Estimated tumor dose of radiation obtained by tissue analysis was 34 and 14 Gy for specific and nonspecific therapy, respectively. In conclusion, 120 μCi of90Y-labeled anti-carcinoembryonic antigen monoclonal antibodies was effective in suppressing growth of human colon cancer xenografts. Clinical studies with this preparation are recommended.

(Arch Surg. 1990;125:660-664)